BioSpace News Archive

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

Curis, Inc. announced that on October 2, 2023, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 11,340 shares of Curis common stock to two new employees, with a grant date of October 2, 2023.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.

GE HealthCare announced its Venue Family point-of-care ultrasound systems will now feature Caption Guidance, artificial intelligence -driven technology that provides real-time guidance to users for capturing diagnostic-quality cardiac images.

enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced a plan to expedite the development of enVVe®, its transcatheter based replacement venous valve.

Cytokinetics, Incorporated announced that the baseline characteristics of patients randomized in SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, were presented at the HCM Society Scientific Sessions in Cleveland, Ohio by Martin S. Maron, M.D., Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center.

Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, has partnered with tech innovator RYLTI to develop an innovative groundbreaking application of AI Knowledge Engineering and use of a biomimetic digital twin ecosystem for advanced genomic research.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2023 results before the market opens on Tuesday, November 7, 2023, to be followed by a conference call at 8:30 a.m. (Eastern Time).